Keywords: final, afcaps, data, confirm, benefits, lowering, average
Final AFCAPS Data Confirm Benefits Of Lowering Average Lipids
Article | 20 April 1998
The final results of AFCAPS/TexCAPS (the Airforce/Texas CoronaryAtherosclerosis Prevention Study) show that lipid-lowering treatment with Merck & Co's Mevacor ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
